The scheme supports the development of technologies with transformative potential to human cardiovascular health from the proof-of-concept stage to being ready for the commercial market. The 3-year project, led by our group, seeks to replace synthetic haemodialysis grafts with a patented biological graft and demonstrate lower risks of infection, thrombosis and other complications, thereby leading to reductions in surgical interventions and reduced demand for hospital access. The work will be carried out in collaboration with different departments across the University (Surgery, Medicine, Queen’s Veterinary School, Wellcome-MRC Cambridge Stem Cell Institute), and Addenbrooke’s and Royal Papworth Hospitals.
More information can be found here.